Skip to main
CRMD

CorMedix (CRMD) Stock Forecast & Price Target

CorMedix (CRMD) Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 43%
Buy 57%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Cormedix is improving its financial position by reiterating its revenue guidance and setting a higher EBITDA guidance for the current fiscal year, as well as expecting potential upside from new products and a potential label expansion for Rezzayo. The company's strong financial results and potential for sustained growth make it an attractive investment opportunity for a financial analyst. Additionally, the company is focused on sustainability and aligning with sustainable finance principles, which could further bolster its long-term prospects. However, there are risks involved with regulatory and commercial development, potential pricing pressure, and competition that could impact the company's rating and stock price.

Bears say

Cormedix is facing challenges in commercializing its product, DefenCath, in the highly competitive market for life-threatening diseases and conditions. While the company has potential upcoming catalysts such as the commercial performance of DefenCath and NDA filing for Rezzayo, there are significant risks to its rating and price target, including regulatory and competition risks. With concentration risk on one anchor customer and potential pricing pressure, and a limited track record in the biopharmaceutical industry, Cormedix's stock outlook appears negative.

CorMedix (CRMD) has been analyzed by 7 analysts, with a consensus rating of Buy. 43% of analysts recommend a Strong Buy, 57% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of CorMedix and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About CorMedix (CRMD) Forecast

Analysts have given CorMedix (CRMD) a Buy based on their latest research and market trends.

According to 7 analysts, CorMedix (CRMD) has a Buy consensus rating as of Aug 30, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $15.86, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $15.86, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

CorMedix (CRMD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.